Evidence map›Paper›PMID 31605162›Full record

ArticleEuropean journal of clinical pharmacology2020

Purchases of medical therapy recommended for coronary artery disease before and after elective revascularisation.

Jari Heiskanen, Juha Hartikainen, Janne Martikainen, Heikki Miettinen, Mikko Hippeläinen, Risto P Roine, Anna-Maija Tolppanen

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jari HeiskanenHeart Center, Kuopio University Hospital, Kuopio, Finland.
Juha HartikainenHeart Center, Kuopio University Hospital, Kuopio, Finland.
Janne MartikainenSchool of Pharmacy, University of Eastern Finland, P.O. Box 1627, Yliopistonranta 1 C, FI-70211, Kuopio, Finland.
Heikki MiettinenHeart Center, Kuopio University Hospital, Kuopio, Finland.
Mikko HippeläinenHeart Center, Kuopio University Hospital, Kuopio, Finland.
Risto P RoineResearch Centre for Comparative Effectiveness and Patient Safety (RECEPS), University of Eastern Finland, Kuopio, Finland.
Anna-Maija TolppanenResearch Centre for Comparative Effectiveness and Patient Safety (RECEPS), University of Eastern Finland, Kuopio, Finland. anna-maija.tolppanen@uef.fi.ORCID http://orcid.org/0000-0001-9270-9268

Funding

European Structural Funds; European Social Fund by Regional Council of North-Savo and State Research Funding reported later, severalFP7 Ideas: European Research Council will be reported laterH2020 European Research Council reported laterTerveyden Tutkimuksen Toimikunta 307232 and 295334
6 · The paper itself

Abstract

aimsWe studied the purchases of medical therapy recommended for coronary artery disease patients before and after elective revascularisation (percutaneous coronary intervention (PCI) or coronary bypass grafting (CABG)).

methodsAll patients who underwent an elective PCI (N = 1557) or CABG (N = 1768) at the Heart Center, Kuopio University hospital between 2007 and 2014 were included. Data were collected from the hospital's coronary register and national registers, and obtained for 3 years before and 1 year after the revascularisation.

resultsAltogether 85.2% of PCI patients and 88.1% of CABG patients had purchased lipid-modifying agents before the procedure, and 94.9% and 96.8% during the post-procedure follow-up year, respectively. Beta-blocking agents were purchased by 84.9% of PCI patients before and by 87.9% after the procedure and by 86.3% of CABG patients before and 97.1% after the operation. Of PCI patients, 64.3% had purchased organic long-acting nitrates before the procedure and 54.4% also after the procedure. Among CABG patients, the purchase of organic long-acting nitrates fell from 59.7% before to 10.1% after the operation. The use of ADP receptor blocking agents increased in PCI patients (26.3 to 83.9%) and the use of warfarin in CABG patients (9.4 to 21.3%). Medication purchases were more common among those who had greater use of hospital services before and after the procedures.

conclusionsIn both PCI and CABG patients, the use of medical therapy before and after revascularisation procedure complied with current guidelines. Purchases of long-acting nitrates were common in the PCI group even after the procedure.

Indexed as

Drug MonitoringAgedCardiovascular AgentsCoronary Artery BypassCoronary Artery DiseaseElective Surgical ProceduresFemaleHumansMalePercutaneous Coronary InterventionPostoperative CarePreoperative CarePrescription DrugsCardiovascular AgentsPrescription DrugsCoronary diseaseEvidence-based medicineHealthcareMedical researchOptimal medical therapyPublic healthRevascularisation

Identifiers

PMID31605162

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.